Video Interview: Corbus Sees 2016 As Pivotal Year
This article was originally published in Scrip
With key clinical data readouts expected at the end of 2016 and the start of 2017, Corbus Pharmaceuticals Holdings Inc.'s CEO Dr. Yuval Cohen expects the next 12 months to be pivotal for the rare inflammatory disease company. Speaking to Informa Pharma Insights global director of content Mike Ward, Cohen reveals that the company expects to report Phase II data for Resunab, its synthetic endocannabinoid-mimetic compound that binds to the CB2 receptor, in both cystic fibrosis and systemic sclerosis. Phase II data for Resunab in dermatomyositis will be available 1Q 2017.